Table 1. Minimal Inhibitory Concentrations (MICs) of R. equi Strains+
Reference |
(111) |
(153) |
(17) |
(31) |
(35) |
Author’s data* |
|
Number of strains |
51 (None human) |
100 animal |
102 (36 human) |
9 |
8 (5 human) |
24 (15 human) |
|
|
MIC90 |
MIC90 |
Range |
Range |
Range |
Range |
Range |
Penicillin |
>2 |
3.12 |
0.1-3.1 |
|
8-16 |
8-16 |
|
Methicillin |
>16 |
50 |
25->100 |
|
|
|
|
Ampicillin |
8 |
6.25 |
0.3-12.5 |
|
|
2-4 |
|
AmoxClavulanate |
|
|
|
|
9 |
|
|
Piperacillin |
|
|
|
|
|
16-32 |
|
Cefotaxime |
|
|
|
|
4-32 |
2-8 |
|
Ceftriaxone |
|
|
|
|
1-8 |
|
|
Ceftazidime |
|
|
|
|
128-256 |
64 |
|
Imipenem |
|
|
|
|
0.25-2 |
0.25 |
|
Erythromycin |
<0.25 |
<0.19 |
<0.19 |
|
0.12-0.25 |
0.12-0.25 |
≤0.06-0.25 |
Clarithromycin |
2 |
|
|
|
0.12 |
|
≤0.06-0.12 |
Clindamycin |
|
|
|
|
|
|
|
Chloramphenicol |
16 |
25 |
1.56-12.5 |
|
|
8 |
|
Tetracycline |
4 |
12.5 |
0.78-25 |
0.25-8 |
|
1-2 |
|
Doxycicline |
|
3.12 |
1.56-12.5 |
|
1-4 |
|
|
Gentamicin |
<0.25 |
0.78 |
0.19-1.56 |
|
0.5-2 |
0.25-0.5 |
|
Amikacin |
≤2 |
|
|
|
2-8 |
0.25-1 |
2-8 |
Vancomycin |
|
|
|
|
0.5 |
0.25-0.5 |
≤0.06-0.5 |
Teicoplanin |
|
|
|
|
0.5 |
|
|
Rifampicin |
|
|
|
|
|
<0.06 |
0.06-16 |
Ciprofloxacin |
|
|
|
|
1-2 |
0.5-1 |
0.25-1 |
Ofloxacin |
|
|
|
|
|
|
0.25-2 |
Premafloxacin |
|
|
|
≤0.008-0.25 |
|
|
|
Enrofloxacin |
|
|
|
<0.03-2 |
|
|
|
Pefloxacine |
|
|
|
|
8-16 |
4-8 |
|
Cotrimoxazole |
32/608 |
50 |
3.12-100 |
|
|
|
|
Sulpha-methoxazole |
|
>100 |
25>100 |
|
|
16-32 |
|
Trimethoprim |
|
50 |
6.25-100 |
|
|
16-64 |
|
Fusidic acid |
|
|
|
|
|
1-2 |
|
Fosfomycin |
|
|
|
|
|
>128 |
|
Linezolid |
|
|
|
0.5-2 |
|
|
|
Eperezolid |
|
|
|
4-16 |
|
|
|
Isoniazide |
|
|
|
|
|
|
>64 |
Ethambutol |
|
|
|
|
|
|
16-64 |
Pyrazinamide |
|
|
|
|
|
|
>64 |
* Cercenado et al. Meeting of the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC) 1996.
Table 2.
Antimicrobial Therapies and Clinical Response in a Literature Review
Antimicrobial therapy
Reference
FAVORABLE RESPONSE
Van + Rifa + Clin
(129)
Van + Cft + Sxt
(51)
Van + Eri + Gen
(10)
Van + Eri + Cip
(98)
Sxt + Ceftri + Netil
(40)
Tei + Cft + Cip
(40)
Eri + Tet + Cli
(68)
Eri + Rif + Sxt
(122)
Eri + Rif + Van
Eri + Rif + Tei
(43)
Eri + Amk
(50)
Eri + Rif
(109)
Van + Dox
(88)
Van + Imp
(117)
Teic + Imp
(28)
Van + Imp
(118)
Cla + Imp
(40)
Van + Eri
(136)
Van + Gen
(146)
Van + Rif
(141)
Imp
Van
PARTIAL RESPONSE
Cla + Rif + Sxt
Eri + Rif + Cip
(83)
Tei + Cip + Clin
(40)
Van + Imp + Netil
(40)
Van + Imp + Tetra
(40)
Teic + Imp+ Eri
(40)
Tei + Imp + Cip + Cft
(40)
Tei + Cip
(27)
Van + Eri
(146)
Van + Eri + Cip
(40)
Imp + Cip
(146)
Imp + Cip + Clin
(146)
Azi
(10)
Chl
(133)
Tet
(88)
Cft
Imp
(26)
Rif + INH + Etb
(118)
Sxt + Amx-Cla + Gen
(109)
Cli + Tet
(150)
Cli + Ctx
(122)
Cli + Gent
(126)
Cip + Chl
(133)
Pen + Gen
(150)
Eri + Cip
(115)
Cla + Cip
(40)
Eri + Cip + Clin
(115)
Eri + Rif
(10)
Van + Amk + Pip
(28)
Van + Rif
(13)
Eri + Clin
NO RESPONSE
Cli
(150)
Cip
(26)
Oflo
(118)
Sxt
(126)
Eri
(126)
Van
(45)
Van + Cft
(51)
Rif + INH + Etb
(110)
Sxt + Amk
(110)
Sxt + Caz
(109)
Cli + Cip
(51)
Cli + Cefonicid
(126)
Eri + Ctx
(118)
Eri + Cip
(98)
Imp + Cip + Clin + Gen
(146)
Van + Gen
(34)
Tei + Amk
(40)
Table 3.
Response to Maintenance Therapy
Antibiotic
|
Relapse control |
Reference |
Cip |
None |
(146) |
Cip |
Favorable |
(136) |
Eri |
Favorable |
(150) |
Eri + Rif |
Favorable |
|
Cla + Rif |
Favorable |
(13) |
Cla + Rif |
None |
(10) |
Eri + Dox |
Favorable |
|
Eri + Tet + Cli |
Favorable |
(68) |
Rox + Dox |
Favorable |
(28) |
Eri + Mnc |
Favorable |
(118) |
Cla + Cip |
Favorable |
(10) |
Cla + Sxt |
Favorable |
(51) |
Tei + Cft |
Favorable |
(28) |
Cli + Pen |
None |
(126) |
Amk, Amikacin; Amx-Cla, Amoxycillin+Clavulanate; Caz, Ceftazidime; Cft, ceftriaxone; Cip, Ciprofloxacin; Cli, Clindamycin; Ctx, cefotaxime; Chl, Chloramphenicol; Dox, Doxyciclin; Eri, Erythromycin; Etb, Ethambutol; Gen, gentamicin; Imp, Imipenem; INH, Isoniazid; Mnc, Minocycline; Ofl, Ofloxacin; Pip, Piperacillin; Rif: Rifampin; Rox, roxithromycin; Tei, Teicoplanin; Tet: Tetracycline Van, Vancomycin